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Mumps Outbreaks at Four Universities — Indiana, 2016
Mugdha Golwalkar, MPH1; Brian Pope1; Jill Stauffer, MS1; Ali Snively1; Nakia Clemmons, MPH2
From February to April 2016, the Indiana State Department 
of Health (ISDH) confirmed mumps outbreaks at four uni-
versities (three public and one private). All universities were 
located within 65 miles of Indianapolis; however, epidemio-
logic links among outbreaks were limited. ISDH and local 
health departments investigated the outbreaks and initiated 
control measures at all universities. A protocol describing 
recommended testing for mumps, testing priorities during 
the outbreak, and a preauthorization process for submitting 
specimens to the ISDH Laboratory (ISDHL) was developed 
and disseminated to providers and public health partners (1). 
Outbreaks at each university were declared over after two 
incubation periods* elapsed without identified cases; the last 
outbreak ended September 10, 2016. Among the 281 con-
firmed and probable cases identified, 216 (76.9%) persons 
had documentation of presumptive evidence of immunity† 
(2). At some universities, documentation of receipt of 2 doses 
of measles, mumps, rubella vaccine (MMR), which is a crite-
rion for evidence of immunity, was not available and required 
substantial personnel time to verify. Implementation of policies 
for excluding susceptible persons from classes and other group 
settings was also difficult. The laboratory testing protocol 
increased the percentage of specimens testing positive and 
improved case detection. Outbreak-specific laboratory testing 
guidance on specimen collection for mumps confirmation and 
standardized vaccination documentation in highly vaccinated 
settings could aid outbreak management. Evaluation of exclu-
sion policies might also be necessary. In 2018, the Advisory 
Committee on Immunization Practices (ACIP) published 
a recommendation that persons previously vaccinated with 
2 doses of MMR who are determined by public health authori-
ties to be part of a group at increased risk for infection during 
a mumps outbreak receive a third dose of MMR (3).
Investigation and Results
On January 20, 2016, a student with unknown mumps vac-
cination history was evaluated at university A’s student health 
center for parotid swelling. The student reported a possible 
mumps exposure at a university outside Indiana, where a large 
mumps outbreak was occurring. Mumps immunoglobulin M 
(IgM) testing was negative, but continuing parotitis motivated 
the university to request reverse transcription–polymerase 
chain reaction (RT-PCR) testing at ISDHL 2 days later, and 
results were positive for mumps. By February 17, 2016, two 
additional cases at university A were confirmed by RT-PCR. 
On January 25, a fully vaccinated student was evaluated at 
university B’s student health center with parotid swelling, 
headache, and fever. Mumps was suspected and reported to 
ISDH; however, laboratory testing was not conducted. On 
February 12, three additional mumps cases with epidemio-
logic links to the index case were confirmed by RT-PCR at 
* The range of the incubation period for mumps virus is 12–25 days after exposure 
(https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm). Two 
incubation periods were calculated using the maximum of the range, totaling 
50 days from the final date of exposure of a university-affiliated case.
† Presumptive evidence of immunity to mumps includes any of the following: 
documentation of age-appropriate vaccination with a live mumps virus–
containing vaccine, laboratory evidence of mumps immunity, laboratory 
confirmation of disease, or birth before 1957.
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university B. On March 11, three cases were confirmed by 
RT-PCR at university C, with no epidemiologic links among 
the patients or to any outside case. On April 2, three cases (one 
confirmed by RT-PCR and two epidemiologically linked) were 
identified at university D; all patients reported possible expo-
sures to mumps during a spring break trip to Florida 2 weeks 
before symptom onset. Additional mumps cases occurred 
in all four universities and in the surrounding community, 
with the last onset date among university-affiliated cases on 
July 18, 2016.
Mumps RT-PCR testing was made available through the 
ISDHL. IgM testing was only offered through commercial 
laboratories. A protocol was developed to assist providers in 
ordering the right testing according to the time elapsed from 
symptom onset, collecting the correct specimens, and obtaining 
preauthorization for testing at ISHDL. Preauthorization required 
consultation with an ISDH epidemiologist to ensure patients 
with suspected mumps met clinical and epidemiologic criteria 
for testing and to ascertain exposure information to prioritize 
testing of specimens from patients without epidemiologic links 
to other cases or suspected cases in new settings. Odds ratios 
and comparison of proportions chi-squared tests were calculated 
to evaluate the impact of specimen collection timing and dis-
semination of testing guidance on specimen positivity. A subset 
of RT-PCR–positive specimens was sent to CDC’s Viral Vaccine 
Preventable Diseases Branch for genotyping.
A total of 281 mumps cases (237 laboratory confirmed and 
44 probable) were identified in all four outbreaks from January 
to September 2016. Among these cases, 179 (63.7%) occurred 
in university students or staff members (university-affiliated 
cases) and 102 (36.3%) in community members not affiliated 
with any of the universities (community cases) (Figure 1). 
Epidemiologic links to university cases were only identified 
in 25.5% of community cases. Signs and symptoms experi-
enced by patients included parotitis (276, 98.2%), fever (109, 
38.8%), headache (74, 26.3%), earache (60, 21.4%), jaw pain 
(16, 5.7%), malaise/body aches (11, 3.9%), and sore throat 
(10, 3.6%). Complications from mumps were infrequent, with 
one report of meningitis and five reports of orchitis.
Receipt of 2 doses of MMR was documented for 152 
(84.9%) of 179 university-affiliated cases and 53 (52.0%) of 
102 community cases; 11 (3.9%) of the 281 cases had docu-
mentation of a positive immunoglobulin G titer. Twelve cases 
(4.3%) had documentation of ≥3 doses of MMR administered 
>4 weeks before parotid swelling onset. In six cases in which 
complications occurred, the persons had each received 2 doses 
of MMR. Seven vaccination clinics were held across three 
schools, and 5,273 doses of MMR were administered, most 
(3,106; 59%) at highly attended clinics at university B. Based 
on high 2-dose MMR coverage at each university, many of 
these doses likely were third doses.
ISDHL tested specimens from 490 suspected cases for con-
firmation by RT-PCR, 209 (42.6%) of which were positive. 
Among 407 cases of suspected mumps for which RT-PCR results 
and onset dates were available, 53.1% (146/275) of specimens 
collected within 2 days of parotitis onset were positive; this 
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decreased slightly to 47.7% (63/132) for specimens collected 
≥3 days after parotitis onset, and the change was not statistically 
significant (Table). Among 63 cases for which IgM results and 
onset dates were available, 34.3% (11/32) of specimens collected 
within 2 days of parotitis onset were positive; the rate of positivity 
increased to 61.3% (19/31) for specimens collected ≥3 days after 
parotitis onset (p<0.05). Among 18 cases for which specimens 
were collected within 5 days of parotitis onset and a RT-PCR 
test was positive, six had results that were IgM positive. Persons 
in 16 of these cases had received 2 MMR doses, and those in 
two cases had received a single dose. Weekly percent positivity 
of specimens submitted to ISDHL increased significantly from 
an average of 25.8% in the weeks before dissemination of the 
laboratory testing protocol to an average of 37.8% (p = 0.005) 
in the weeks after dissemination (Figure 2). CDC provided 
genotyping for 142 specimens; 140 (98.6%) were type G (the 
most common genotype circulating in the United States), and 
two were unable to be genotyped.
Public Health Response
Cases were classified according to the Council of State and 
Territorial Epidemiologists case definition for mumps (4), and 
a mumps outbreak was defined as three or more cases linked by 
place and time. Cases were considered infectious from 2 days 
before until 5 days after onset of parotitis. Control measures 
included isolation recommendations for persons with sus-
pected infections, dissemination of educational materials on 
case finding, verification of vaccination status for persons and 
their close contacts in all cases, and MMR vaccination clin-
ics at three of the four universities. Because recent studies on 
third-dose vaccine effectiveness were limited and had varying 
results (5,6), and because there was no formal ACIP recom-
mendation regarding use of a third dose of MMR for persons 
affected in an outbreak at the time, no university specifically 
recommended a third dose of MMR to students. However, in 
addition to recommending to students that they attend clinics 
for catch-up doses of MMR, students were advised that they 
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FIGURE 1. Number of confirmed (N = 237) and probable (N = 44) mumps cases associated with outbreaks at four universities, by week of onset 
and dates of MMR vaccination clinics — Indiana, January–September 2016
Abbreviation: MMR = measles, mumps, and rubella vaccine.
TABLE. Positivity of patient specimens for mumps, by testing method 
and time from symptom onset to specimen collection — Indiana, 2016
Time from onset to 
specimen collection
Result no. (%)
OR (95% CI)†Positive
Negative/
Indeterminate*
RT-PCR
0–2 days 146 (53.1) 129 (46.9) 0.81 (0.53–1.22)
≥3 days 63 (47.7) 69 (52.3)
IgM
0–2 days 11 (34.3) 21 (65.6) 3.02 (1.08–8.44)§
≥3 days 19 (61.3) 12 (38.7)
Abbreviations: CI = confidence interval; IgM = immunoglobulin M; OR = odds 
ratio; RT-PCR = reverse transcription–polymerase chain reaction.
* RT-PCR values were considered indeterminate if replicates were discordant on 
two separate runs. Three specimens were ruled indeterminate.
† ORs and 95% CIs were calculated for test results relative to time from symptom 
onset to specimen collection, with specimen collection ≥3 days after symptom 
onset as the reference.
§ Significant at p<0.05 level.
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could receive vaccine if previous MMR vaccination documen-
tation was unavailable or if an additional dose was desired.
Current immunization policies in Indiana require universi-
ties to collect immunization information from matriculating 
students at certain institutions, but guidance on record format 
and verification is limited (7). Each university had different 
documentation requirements for immunization records. Only 
two universities (B and D) required documentation of dose 
and month/day/year administration date, and only university B 
required provider verification of records.
Although isolation through 5 days after parotid swelling 
onset was recommended for all patients and exclusion from 
classes, work, or public gatherings was recommended for 
contacts without presumptive evidence of immunity, only 
university B was able to successfully ensure both isolation and 
exclusion by requiring either off-campus isolation or exclusion 
at home and providing alternative living arrangements for stu-
dents who could not isolate or self-exclude off-campus Because 
most cases were occurring in fully vaccinated persons for whom 
no exclusion would be recommended by susceptibility-based 
exclusion policies, the benefit of enforcement was questioned, 
and it was difficult to garner buy-in to expend already limited 
personnel resources on enforcing these policies. Affected per-
sons and contacts at universities A and C would have needed 
to acquire appropriate documentation of immunization from 
family or providers. Because of time-related difficulties in doing 
this, only close contacts were required to provide presumptive 
evidence of immunity for determining if exclusion was needed. 
At all universities, students without presumptive evidence of 
immunity were offered the option of receiving a dose of MMR 
and returning to campus.
Discussion
Mumps is an acute viral illness characterized by parotid 
gland swelling that can result in more serious complications 
such as orchitis and encephalitis. A substantial increase in the 
number of mumps outbreaks and outbreak-associated cases has 
occurred in the United States since late 2014 (8). Four large 
university mumps outbreaks with considerable community 
spread occurred in Indiana in 2016, contributing to the 6,366 
mumps cases reported nationwide in 2016, the highest number 
of cases in a decade. In Indiana, epidemiologic links to the 
university outbreaks or to other cases could not be identified 
for many community cases. This might indicate gaps in current 
case finding and linkage methods, asymptomatic transmission, 
or underreporting of mumps cases during nonoutbreak periods.
Laboratory testing is an important component of confirming 
mumps cases and outbreaks. Availability of a detailed outbreak-
specific testing protocol possibly improved the overall positivity rate 
of specimens tested at ISDHL during the course of these outbreaks. 
Detection of mumps virus by RT-PCR was higher among specimens 
collected ≤2 days from parotid swelling onset, supporting previous 
findings of higher rates of positivity within 3 days of parotitis onset 
(6,9,10). Results of serologic testing support concerns regarding 
poor sensitivity of routine diagnostic commercial IgM testing in 
vaccinated persons in low-incidence settings (10).
The occurrence of these outbreaks highlights the need for 
immunization documentation requirements at institutions of 
higher education to be standardized and consistent with ACIP 
and state recommendations for documentation of presumptive 
evidence of immunity (2). As a result of this investigation, both 
universities A and C implemented requirements for collecting 
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FIGURE 2. Number and percentage of specimens testing positive for mumps by reverse transcription–polymerase chain reaction, by week — 
Indiana State Department of Health Laboratories, 2016
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provider-verified month/day/year immunization records for 
all matriculating full-time students beginning in fall 2017. 
Although policies on exposed contact exclusion that are depen-
dent on vaccination status can ease some difficulties in outbreak 
management by quickly identifying persons without evidence of 
immunity, these policies may be insufficient for outbreak con-
trol at institutions of higher education with high 2-dose MMR 
coverage (i.e., most persons and contacts are fully vaccinated). 
A recent ACIP recommendation states that persons previously 
vaccinated with 2 doses of MMR who are determined by health 
departments to belong to groups or populations at increased 
risk during a mumps outbreak be given a third dose of MMR 
to improve individual protection (3). Conducting vaccination 
clinics to provide these doses could allow multiple individuals 
to be vaccinated at once at low or no cost to students and staff 
members and provide an opportunity for health department 
personnel to educate individuals in the outbreak setting on 
signs and symptoms of mumps and ways to avoid infection. If 
outbreak management in populations with high 2-dose cover-
age continues to be a challenge for public health authorities 
despite the recommendation for use of a third dose of mumps-
containing vaccine during outbreaks, reevaluation of current 
recommended exclusion measures could be warranted (1,3). 
Given the challenges in managing and controlling outbreaks in 
university settings, documenting and maintaining high 2-dose 
coverage of MMR in this setting is especially important.
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Summary
What is already known about this topic?
Recently, mumps outbreaks among vaccinated persons in 
university settings have increased.
What is added by this report?
In 2016, large mumps outbreaks occurred at four Indiana 
universities. At some universities documentation of receipt of 
2 doses of measles, mumps, and rubella vaccine (MMR) was not 
available and required substantial personnel time to verify. 
Implementation of policies for excluding susceptible persons 
from classes and other group settings was also difficult. 
What are the implications for public health practice?
Outbreak-specific laboratory testing guidance to partners, standard-
ized vaccination documentation, and evaluation of exclusion policies 
could aid outbreak management. The Advisory Committee on 
Immunization Practices currently recommends a third dose of MMR 
for persons at increased risk during a mumps outbreak.
